CDK12 Mutation Targeted Therapy for Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional diagnostic and treatment options for prostate cancer, particularly for patients with metastatic prostate cancer that have failed hormone therapy, as current treatments like taxane-derived chemotherapies are not durable and do not effectively target specific tumor mutations.
Innovation Solution
The development of targeted therapies, specifically checkpoint inhibitor immunotherapy and cell cycle protein inhibitors, tailored for patients with CDK12 mutations, which involve detecting CDK12 mutations in prostate cancer samples and administering appropriate immunotherapies such as anti-PD-1 agents or inhibitors of cell cycle proteins like CCND1, CCND2, CCND3, CCNE1, or CDK4.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If taxane-derived chemotherapeutic agents are used for metastatic prostate cancer, then treatment response is achieved, but response duration is short and progression-free survival approaches 0% by 3 years
Solution Approach 1:
The patent changes the therapeutic parameter from conventional chemotherapy to checkpoint inhibitor immunotherapy based on the detection of CDK12 mutation status. This parameter change enables durable responses in patients with CDK12 mutations, directly addressing the short response duration problem of taxane-derived agents.
2Ease of manufacture
If conventional therapies are used for prostate cancer, then treatment is administered, but therapies do not effectively target specific tumor mutations
Solution Approach 1:
The patent segments prostate cancer patients into distinct molecular subgroups based on CDK12 mutation status. This segmentation enables customized treatment selection: checkpoint inhibitor immunotherapy for CDK12-mutated patients and conventional therapies for others, thereby achieving treatment customization while maintaining broad availability.
Solution Approach 2:
The patent applies different treatment qualities to different patient subgroups based on their molecular characteristics. CDK12-mutated patients receive checkpoint inhibitor immunotherapy with durable responses, while other patients receive conventional therapies, ensuring each patient receives the most appropriate treatment for their specific tumor biology.
3Quantity of substance
If checkpoint inhibitor immunotherapy is administered to all prostate cancer patients, then treatment coverage is maximized, but treatment effectiveness is reduced due to lack of target selection
Solution Approach 1:
The patent performs preliminary detection of CDK12 mutation status before administering checkpoint inhibitor immunotherapy. This preliminary action identifies the specific patient subgroup (CDK12-mutated) most likely to benefit, ensuring treatment effectiveness is maximized while maintaining appropriate coverage for this target population.
Data Source
AI summary
Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of targeted therapy to treat cancer (e.g., prostate cancer) in subjects with CDK12 mutations.